Internalized antibodies to the Aβ domain of APP reduce neuronal Aβ and protect against synaptic alterations

108Citations
Citations of this article
89Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Immunotherapy against β-amyloid peptide (Aβ) is a leading therapeutic direction for Alzheimer disease (AD). Experimental studies in transgenic mouse models of AD have demonstrated that Aβ immunization reduces Aβ plaque pathology and improves cognitive function. However, the biological mechanisms by which Aβ antibodies reduce amyloid accumulation in the brain remain unclear. We provide evidence that treatment of AD mutant neuroblastoma cells or primary neurons with Aβ antibodies decreases levels of intracellular Aβ. Antibody-mediated reduction in cellular Aβ appears to require that the antibody binds to the extracellular Aβ domain of the amyloid precursor protein (APP) and be internalized. In addition, treatment with Aβ antibodies protects against synaptic alterations that occur in APP mutant neurons. © 2007 by The American Society for Biochemistry and Molecular Biology, Inc.

Cite

CITATION STYLE

APA

Tampellini, D., Magrané, J., Takahashi, R. H., Li, F., Lin, M. T., Almeida, C. G., & Gouras, G. K. (2007). Internalized antibodies to the Aβ domain of APP reduce neuronal Aβ and protect against synaptic alterations. Journal of Biological Chemistry, 282(26), 18895–18906. https://doi.org/10.1074/jbc.M700373200

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free